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a  b  s  t  r  a  c  t
Background:  The  effects  of  glucocorticoids  on  viral  myocarditis  are  contentious.  The  aim  of  the  present
study  was  to  determine  whether  there  is a “window  of  opportunity”  for glucocorticoid  treatment  in  a
mouse model  of acute  viral  myocarditis  induced  by Coxsackie  group  B3  virus  (CVB3).
Methods:  A/J  (H-2a)  mice  were  randomly  assigned  to  one  of  four experimental  groups:  (1) viral  infection
without  dexamethasone  (DEX)  treatment;  (2)  treatment  with  0.75  mg/kg,  i.p.,  DEX  each  day  for  5  days
prior to viral  infection;  (3)  0.75  mg/kg,  i.p.,  DEX  treatment  for 5 days  immediately  after  viral  infection;
and  (4)  0.75  mg/kg,  i.p.,  DEX  treatment  for  5 days  starting  on day  7  after  infection.
Results:  DEX  administration  before  or immediately  after  viral  infection  improved  survival  and  attenuated
left ventricular  dilatation,  systolic  dysfunction,  ﬁbrosis,  and  inﬁltration  of  immune  cells  in the  post-
infectious  heart.  In contrast,  late  administration  of DEX  reduced  survival  (as  determined  on day  14),  and
was associated  with  sustained  increases  in  cardiac  tumor  necrosis  factor-  and  interferon-  levels.  The
beneﬁcial  effects  of  early  DEX  administration  on survival  were  completely  abrogated  by  coadministration
of  a selective  cyclooxygenase  (COX)-2  inhibitor  (NS-398;  5 mg/kg  per  day,  p.o.).  Notably,  the virus  titer
in the  post-infectious  heart was  signiﬁcantly  suppressed  by  DEX,  but  coadministration  of  NS-398  at  the
time  of viral  infection  abolished  the  suppressive  effects  of  DEX  and, in fact,  increased  virus  titers.
Conclusions:  Early  administration  of  DEX  is beneﬁcial  in  the  treatment  of  fulminant  viral  myocarditis,
whereas  late  administration  of DEX  is harmful.  The  beneﬁcial  effects  of  DEX  on  survival  were  completely
abolished  by simultaneous  administration  of  a selective  COX-2  inhibitor.  Hence,  we speculate  that  a direct
action  of DEX  on  cardiomyocytes,  rather  than  anti-inﬂammatory  effects  of  DEX  on  immune  cells,  confers
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Long-term morbidity and mortality of viral myocarditis are
elated to abnormal immune responses and inﬂammation, thus
mmunosuppression was considered beneﬁcial in the treatment of
yocarditis. However, two randomized clinical trials [1,2] failed
o conﬁrm any beneﬁcial effects of immunosuppressive therapy
consisting of prednisone alone or in combination with either
yclosporin or azathioprine) in patients with myocarditis. On
he basis of these ﬁndings, there is now a consensus among
ardiologists that immunosuppressive agents should not be
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prescribed routinely for the treatment of viral myocarditis.
Nevertheless, steroids are often administered in addition to hemo-
dynamic support for patients with fulminant myocarditis, with this
treatment regimen reported to be successful [3–5].
The ability of glucocorticoids (GCs) to limit the acute inﬂam-
matory response is well accepted. GCs act on leukocytes and
endothelial cells to attenuate leukocyte–endothelial cell interac-
tions and to reduce the generation and release of proinﬂammatory
cytokines and mediators. However, little is known about the
genomic actions of GCs on cardiomyocytes. The glucocorticoid
receptor (GR) is expressed abundantly in cardiomyocytes, and
so steroid therapy may  directly affect the gene expression pro-
ﬁle of cardiomyocytes. Previously, we  demonstrated that selective
activation of the GR upregulated cyclooxygenase (COX)-2 and
prostaglandin (PG) biosynthesis in cardiomyocytes, and that this
phenomenon was responsible for GR-mediated cardioprotection
against ischemia–reperfusion injury [6].  The importance of PGs in
vier Ltd. All rights reserved.





















































Fig. 1. (A) Diagram showing the different treatment protocols. Mice were randomly
assigned to one of four experimental groups: (1) viral infection without dexametha-
sone (DEX) treatment (no treatment); (2) daily DEX treatment for the 5 days prior
to  viral infection (DEX preinfection); (3) daily DEX treatment for the 5 days imme-
diately after viral infection (DEX early postinfection); and (4) DEX treatment for 5
days starting on day 7 after infection (DEX delayed postinfection). All surviving mice
were killed for histological evaluation 14 days after viral inoculation. (B) Diagram
showing the experimental protocol for simultaneous administration of NS-398 or38 H. Nakamura et al. / Journal
he pathology of inﬂammation is evidenced by the success of COX-
 inhibitors in mitigating such conditions. However, PGs seem to
ave protective effects in the heart, where COX-2 inhibitors have
een reported to worsen a variety of pathophysiological conditions
n mice, including ischemia–reperfusion injury [7],  left ventricular
emodeling after myocardial infarction [8],  doxorubicin-induced
yocardial injury [9],  and acute viral myocarditis [10]. The use of
onsteroidal anti-inﬂammatory drugs during myocarditis has also
een associated with increased mortality [11].
The aim of the present study was therefore to determine
hether there is a “window of opportunity” for the use of GCs
n the treatment of acute viral myocarditis and, if so, to evaluate
he role of COX-2 activity in the cardioprotection conferred by GC
reatment.
ethods
This study was approved by the Institutional Animal Care
nd Use Committee of Yamaguchi University and was  per-
ormed in accordance with the guidelines of the American Heart
ssociation and Yamaguchi University School of Medicine, as
ell as Law No. 105 and Notiﬁcation No. 6 of the Japanese
overnment.
nimals and experimental protocols
Coxsackievirus B3 (CVB3; Nancy strain), an important human
athogen that induces acute viral myocarditis, was  obtained from
merican Type Culture Collection and stored at −80 ◦C until use.
hree-week-old, inbred, certiﬁed virus-free A/J (H-2a) male mice
ere purchased from Japan SLC (Shizuoka, Japan). A/J (H-2a) mice
re susceptible to CVB3-induced myocarditis and develop a severe
ourse of acute viral myocarditis. A/J (H-2a) mice that were not
nfected with the virus served as the control group. All mice were
nitially infected by i.p. injection of 2 × 104 plaque-forming units
p.f.u.) CVB3 in 0.2 mL  saline.
Following inoculation, mice were randomly assigned to one of
our treatment groups (n = 10 mice per group) and injected with
ither 0.75 mg/kg, i.p., dexamethasone (DEX) or a similar volume of
he vehicle control (2% dimethyl sulfoxide). As indicated in Fig. 1A,
he four treatment groups were: (1) virus infection without DEX
dministration (no DEX treatment); (2) DEX treatment for the
 days prior to virus infection (DEX preinfection); (3) DEX treat-
ent for the 5 days immediately after virus infection (DEX early
ostinfection); and (4) DEX treatment for 5 days starting on day 7
fter infection (DEX delayed postinfection).
Infected mice were isolated, ﬁve per cage, in a special unit for
4 days. After 14 days, the mice were anesthetized with 5% pen-
obarbital (0.015 mL/g) and their hearts removed. The hearts were
ut in half along the midline, with one half ﬁxed in 10% buffered
ormalin and embedded in parafﬁn according to standard proce-
ures, and the other half were plunged into liquid nitrogen and
hen stored until use.
In some experiments (Fig. 1B), mice were co-administered
 mg/kg per day, p.o., NS-398 (a selective COX-2 inhibitor; EMD  Bio-
ciences, Darmstadt, Germany; Fig. 1B), starting at the same time
s viral inoculation [10].
orphometry and histopathology
Parafﬁn-embedded ventricular tissues were cut into 4-m sec-
ions and stained with hematoxylin–eosin and Azan solution.
eft ventricular dimensions and wall thickness were measured
sing the transverse section of the middle portion of each ven-
ricle. The cavity dimensions and the wall thickness of thevehicle (0.9% normal saline) with virus inoculation. PFU, plaque-forming units.
left ventricle were calculated using the methods described by
Takata et al. [12].
Immunohistochemistry
Ventricular tissues frozen in OCT compound (Miles, Elkhart, IN,
USA) and stored at −80 ◦C were used for immunoenzymatic stain-
ing. Frozen samples were cut into 4-m sections and stained using
a DAKO LSAB kit (Dako, Carpinteria, CA, USA) according to the man-
ufacturer’s instructions. The primary antibody used was against
murine lymphocytes (anti-mouse CD45; R&D, Minneapolis, MN,
USA). The intensity of immunostaining was graded semiquantita-
tively on a three-point scale as follows: 1+, positive staining in <10%
of cells; 2+, positive staining in 10–30% of cells; and 3+, positive
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etermination of virus titers and cytokine levels in mouse hearts
The CVB3 titers in hearts were determined in terms of viral
ytopathic effects and are expressed as the tissue culture mean
nfectious dose (TCID50). Brieﬂy, hearts were partially homogenized
n 2 mL  minimal essential medium (MEM). After centrifugation of
amples, the supernatants were added to 96-well microtiter plates
ontaining human amnion cells in MEM  supplemented with 10%
etal calf serum. The microtiter plates were observed daily over a
eriod of 5 days for the appearance of any cytopathic effects [10].
issue concentrations of tumor necrosis factor (TNF)- and inter-
eron (IFN)-  were determined as described in detail elsewhere
15].
tatistical analyses
Data are expressed as the mean ± SEM. Differences between
roups were assessed using one-way ANOVA and Fisher’s post hoc
est. Descriptive statistics of mean survival time are expressed
s the mean ± SD and as survival curves, constructed using the
aplan–Meier method. Log-rank tests were used to compare sur-
ival times among the different groups. All p-values are two-sided,
nd p < 0.05 was considered signiﬁcant. All statistical analyses were
erformed using SPSS 16.0J (SPSS Japan, Tokyo, Japan).
esults
ffects of the timing of DEX administration on survival outcome
To investigate the timing effects of GC treatment of myocarditis,
ice were assigned to different groups with varied DEX adminis-
ration regimens (Fig. 1A). Fig. 2A shows the survival curves for
ice in each of the different groups 14 days after virus infec-
ion. The survival rate for mice that did not receive any DEX
reatment was 40% (4/10). In contrast, the survival rate for mice
reated with DEX either 5 days prior to infection or 5 days imme-
iately after infection was 100% (10/10 in each group). Finally,
elayed DEX treatment, starting 7 days after infection, had no
eneﬁcial effect on survival, with a 0% (0/10) survival rate in this
roup.
ffects of the timing of DEX administration on post-myocarditis
ardiac remodeling
Hearts were removed from mice surviving 14 days after infec-
ion to evaluate changes in left ventricular geometry, systolic
unction, pathohistology, and virus titers. Azan staining revealed
arked ventricular ﬁbrosis in hearts from the no DEX treatment
roup (Fig. 2B). However, DEX treatment either before or imme-
iately after infection signiﬁcantly attenuated the development
f ﬁbrosis. As indicated in Fig. 2C, the left ventricular dimen-
ions in the DEX preinfection and early postinfection groups were
igniﬁcantly lower than those in the no DEX treatment group
2.27 ± 0.07 mm and 2.10 ± 0.09 mm vs 3.11 ± 0.17 mm,  respec-
ively). There was a signiﬁcant increase in wall thickness in
he DEX preinfection and DEX early postinfection groups com-
ared with the no DEX treatment group (0.68 ± 0.05 mm and
.68 ± 0.02 mm vs 0.52 ± 0.05 mm,  respectively; Fig. 2D). DEX
reatment either before or immediately after infection signiﬁ-
antly reduced cell inﬁltration compared with that in the no DEX
reatment group (2.0 ± 0.0 and 1.6 ± 0.3 vs 2.8 ± 0.2, respectively;
ig. 2E).
We  could not evaluate the effects of delayed DEX administra-
ion on post-myocarditis cardiac remodeling because there werediology 61 (2013) 237–242 239
no survivors in the DEX delayed postinfection group 14 days after
infection.
Effects of the timing of DEX administration on virus titers
The anti-remodeling effects of both preinfection and early
postinfection DEX on acute myocarditis led us to investigate the
mechanisms involved. First, we  examined the time course of
changes in tissue virus titers after viral inoculation (Fig. 3A). The
TCID50 value reached maximum levels on day 3 and decreased
thereafter. Therefore, we compared tissue virus titers on day
3 after inoculation in the no DEX treatment, DEX preinfec-
tion, and DEX early postinfection groups. As shown in Fig. 3B,
TCID50 values on day 3 after inoculation were signiﬁcantly
lower in both DEX-treated groups compared with the untreated
group.
Role of COX-2 in DEX-stimulated antiviral responses
It is well known that DEX exerts its anti-inﬂammatory effects
by suppressing COX-2-mediated PG biosynthesis in immune cells.
Furthermore, we reported previously that selective activation of
the GR in cardiomyocytes upregulates COX-2 and PG biosynthesis,
and that this phenomenon is responsible for GC-mediated car-
dioprotection against ischemia–reperfusion injury [6].  Thus, the
favorable effects of DEX on survival and left ventricular remodeling
in the present study may  be due to the anti-inﬂammatory effect of
DEX on immune cells, a direct action of DEX on cardiomyocytes,
or both.
To investigate the mechanisms underlying the effects of DEX on
survival and left ventricular remodeling, mice were injected with
5 mg/kg per day, i.p., NS-398, a selective COX-2 inhibitor, or an
equal volume of vehicle (0.9% normal saline) simultaneously with
virus inoculation (Fig. 1B) and the effects on survival and virus titers
determined. Consistent with previous reports [10], NS-398-treated
mice were more susceptible to the effects of CVB3 injection than
vehicle-treated mice (Fig. 4A), with all NS-398-treated mice dying
within 2 days after infection.
The effects of COX-2 inhibition on the favorable survival out-
come in DEX-treated mice with CVB3-induced acute myocarditis
were evaluated. We conﬁrmed that DEX administration before
or immediately after virus infection improved survival in mice
with acute myocarditis. Notably, the favorable effects of DEX on
post-infection survival were abolished by NS-398 treatment in
both the DEX preinfection and DEX early postinfection groups
(Fig. 4A).
We  also examined the effects of COX-2 inhibition on tissue
virus titers 24 h after infection in the no DEX treatment and
DEX preinfection groups (Fig. 4B). Mice injected with NS-398
that did not receive DEX treatment died within 48 h. Twenty-four
hours after infection, virus titers in the heart were signiﬁcantly
lower in the DEX preinfection group compared with the no DEX
treatment group (TCID50 1.10 ± 0.39 × 105 vs 2.43 ± 0.91 × 105,
respectively; Fig. 4B). NS-398 administration at the time of virus
infection abolished the inhibitory effect of DEX  on virus titers and,
indeed, accelerated virus multiplication (TCID50 6.79 ± 0.92 × 105;
Fig. 4B).
Effects of delayed DEX administration on the resolution of viral
infection and inﬂammation
To examine the mechanisms involved in the detrimental effects
of delayed DEX administration after infection, we measured tissue
levels of inﬂammatory cytokines. Levels of TNF- and IFN- in
hearts from mice in the no DEX treatment group increased after
infection, peaking on day 5 before decreasing again (Fig. 5A). In
240 H. Nakamura et al. / Journal of Cardiology 61 (2013) 237–242
Fig. 2. (A) Kaplan–Meier estimates of mortality on day 14 after viral inoculation in the no treatment, dexamethasone (DEX) preinfection, DEX early postinfection, and DEX
delayed postinfection groups (n = 10 in each group). *p < 0.05 compared with the DEX preinfection or DEX early postinfection groups; †p < 0.05 compared with the no DEX
treatment group. (B) Photomicrographs showing cross-sections of hearts from the DEX preinfection, DEX early postinfection, and no DEX treatment groups (Azan stain).








cC–E)  Left ventricular dimension (C), wall thickness (D), and semiquantitative analy
roups.  Data are the mean ± SD; *p < 0.05.
ontrast, levels of both TNF- and IFN- were elevated in hearts
rom mice in the DEX delayed postinfection group 10 days after
nfection (Fig. 5B).
iscussionThe results of the present study demonstrate that there is a
window of opportunity” for the use of GCs in the treatment of
ulminant viral myocarditis in a mouse model. Infection with CVB3
auses fulminant viral myocarditis, resulting in ventricular dilationhe inﬁltration of inﬂammatory cells (E) in cardiac cross-sections from the different
that leads to cardiac insufﬁciency and eventually premature death.
Administration of DEX prior to or soon after viral infection in the
present study improved survival and prevented post-myocarditis
cardiac remodeling. In contrast, DEX administration starting 7 days
after infection had detrimental effects on outcome. In our mouse
model of acute fulminant myocarditis, virus titers peaked on day 5
after infection, whereas myocardial inﬂammation peaked on day 7.
Therefore, DEX administration starting 7 days after infection
corresponds to treatment during the resolution phase of the
inﬂammation.
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Fig. 3. (A) Time course of changes in virus titers in the heart after Coxsackie group B3
virus (CVB3) inoculation in the no dexamethasone (DEX) treatment group (n = 5 for
each time point). (B) Virus titers in the myocardium on day 3 after viral inoculation




























Fig. 4. (A) Kaplan–Meier estimates of mortality on day 14 after viral inoculation in
the  no treatment, dexamethasone (DEX) preinfection, and DEX early postinfection
groups with or without NS-398 treatment on day 0 (n = 10 for each group). *p < 0.05
compared with the no treatment without NS-398 group; †p < 0.05 compared with
the DEX preinfection without NS-398 group; ‡p < 0.05 compared with the DEX early
postinfection without NS-398 group. (B) Virus titers in the myocardium in different
groups on day 1 after inoculation. TCID50, tissue culture mean infectious dose. DataCID50, tissue culture mean infectious dose. Data are the mean ± SEM; *p < 0.05.
The favorable effects of DEX on the outcomes of fulminant viral
yocarditis are not simply a reﬂection of its anti-inﬂammatory
ction. Generally speaking, the anti-inﬂammatory effects of DEX
re associated with suppression of COX-2-mediated PG biosynthe-
is in immune cells. However, in the present study, the beneﬁcial
ffects of DEX on survival were completely abolished by the
imultaneous administration of a selective COX-2 inhibitor at the
ime of viral infection. DEX stimulates COX-2 expression and
ugments COX-2-mediated prostanoid biosynthesis in cardiomy-
cytes. Previous studies have demonstrated that pharmacological
nd genetic defects of COX-2 do not attenuate, but rather enhance,
yocardial damage from viral myocarditis [11]. Together, these
ndings suggest that a direct action of DEX on cardiomyocytes
lays a crucial role in cardioprotection during the acute phase
f viral myocarditis. To determine precisely how DEX treatment
onfers cardioprotection in the setting of acute viral infec-
ion, future studies are needed in cell type-speciﬁc GR-knockout
ice [16].
In the present study, we also demonstrated that early DEX treat-
ent suppresses virus titers in the post-infection myocardium.
ntiviral activities of PGs have been documented. However, even
hough it is known that PGs affect the replication of a variety of
NA and DNA viruses, their mode of action remains to be clariﬁed.
ipocalin-type prostaglandin-D synthase (L-PGDS) is abundantly
xpressed on cardiomyocytes, and PGD2 is the main PG produced
y DEX. PGD2 inhibits the replication of bovine herpesvirus 1
y impairing the transactivation ability of immediate early pro-
ein BICP0, which is necessary for efﬁcient virus replication [15].are  the mean ± SD (n = 10 in each group); *p < 0.05.
Notably, in the present study, virus titers in hearts 24 h after infec-
tion were signiﬁcantly suppressed by DEX, whereas this effect was
abolished by the selective COX-2 inhibitor NS-398 (administered
at the time of viral infection); indeed, NS-398 even enhanced viral
multiplication. These ﬁndings suggest that L-PGDS-derived PGD2
controls CVB3 replication.
The mechanisms underlying the detrimental effects on survival
following DEX administration during the late post-infection stage
can be explained by the existence of two distinct phases of inﬂam-
mation. The initial proinﬂammatory phase of the host response
to viral infection is followed by a late reparative phase. DEX
administration during the late post-infection stage in the present
study may  have mitigated the naturally occurring resolution of
inﬂammation.
Because patients generally present days to weeks after initial
viral infection, steroid therapy at the optimal time has limited
application in patients with acute viral myocarditis. Nevertheless,
steroid therapy can be beneﬁcial for the treatment of fulminant
viral myocarditis during the acute phase via multiple mechanisms,
including augmentation of the defense response in cardiomyocytes,
inhibition of virus replication, and an anti-inﬂammatory effect
against immune cells. Prophylactic administration of antipyretic
drugs, such as COX-2 inhibitors, for viral myocarditis should no
242 H. Nakamura et al. / Journal of Car
Fig. 5. (A) Time course of changes in tissue tumor necrosis factor (TNF)- and
interferon (IFN)-  concentrations after inoculation with Coxsackie group B3 virus
(CVB3) in the no dexamethasone (DEX) treatment group. *p < 0.05 compared with















[f  TNF- and INF- on day 3 after viral inoculation in the no DEX treatment and
EX delayed postinfection groups. Data are the mean ± SEM (n = 5 in each group);
p  < 0.05.
onger be routinely recommended without careful consideration
f the expected beneﬁts and risks.
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